Table 2a.
Summary results of the two Delphi consultations.
| - | First Round | Second Round | |||||
| Mean Score | Agreement on 4 and 5 |
Index of
Dispersion |
Mean Score | Agreement on 4 and 5 | Index of Dispersion | ||
| A | Therapeutic Appropriateness in the Management of Adult Patients (>18 Years) with SCZ | - | - | - | - | - | - |
| 1 | In the management of a schizophrenic patient, the evaluation of the stage of the disease is decisive for the therapeutic choice. | 4.4/5 | 92.9% | 33.0% | 4.5/5 | 94.2% | 30.3% |
| 2 | Second-generation antipsychotics should be preferred over first-generation antipsychotics as they are associated with better functional outcomes and less cognitive impairment. |
4.5/5 | 95.7% | 28.6% | 4.6/5 | 95.7% | 28.3% |
| 4 | Cariprazine, in addition to affecting negative and positive symptoms by acting on D3 receptors, also produces an improvement in cognitive symptoms (attention, concentration) facilitating psychosocial rehabilitation treatments. | 4.1/5 | 85.7% | 33.4% | 4.1/5 | 88.4% | 30.9% |
| 7 | In acute SCZ, associated with positive and negative symptoms, cariprazine could be useful, especially in young patients with relatively short disease duration. |
4.2/5 | 88.6% | 34.9% | 4.2/5 | 89.9% | 35.5% |
| 8 | Cariprazine is appropriate in patients with SCZ-spectrum disorders and substance abuse as it can reduce cravings. | 3.9/5 | 71.4% | 38.7% | 4.0/5 | 81.2% | 35.1% |
| 9 | It is advisable to start treatment with cariprazine using the minimum recommended dosage of 1.5 mg once a day. | 4.2/5 | 82.9% | 44.4% | 4.3/5 | 91.3% | 38.3% |
| 3 | In schizophrenic patients with predominantly negative symptoms, first- and second-generation antipsychotics have shown partial efficacy. | 3.7/5 | 71.4% | 59.9% | Statement modified for the second consultation | ||
| 3 | First- and second-generation antipsychotics have shown partial efficacy in countering the negative symptoms of SCZ. |
Statement modified from the first consultation |
3.7/5 | 69.6% | 60.6% | ||
| 5 | In schizophrenic patients with early psychotic onset with hostility, the use of cariprazine is appropriate. | 3.3/5 | 51.4% | 60.4% | Statement modified forthe second consultation | ||
| 5 | The use of cariprazine is appropriate in psychotic beginnings with hostile behavior. | Statement modified from the first consultation |
3.4/5 | 49.3% | 56.8% | ||
| 6 |
In patients with SCZ-spectrum disorders and agitation
(also in combination with a second drug, e.g., benzodiazepine) the use of cariprazine is appropriate. |
3.5/5 | 60.0% | 55.8% | Statement modified for the second consultation | ||
| 6 | The use of cariprazine (also in combination with a second drug) is appropriate in psychotic episodes with motor agitation. |
Statement modified from the first consultation |
3.6/5 | 60.9% | 56.3% | ||